Skip to main content

Corporate insider profile

Michael H. Mulroy Insider Trades

Michael H. Mulroy has reported 1 open-market purchase on SEC Form 4 and is a net buyer of $26,100 across 1 company. The most recent open-market transaction was reported on Nov 17, 2026. Source: SEC Form 4 filings.

Latest reported as Director of Lineage Cell Therapeutics, Inc. (LCTX).

SEC-reported filing activity is provided for research purposes and is not investment advice.

Purchase filings
1
Reported companies
1
Net open-market value
$26,100
Latest transaction
Nov 17, 2026

Affiliated corporations

Reported company relationships

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Nov 17, 2026Lineage Cell Therapeutics, Inc. (LCTX)DirectorOpen Market Purchase30,000$0.87$26,100

Common questions

Michael H. Mulroy insider trading FAQ

Is Michael H. Mulroy buying or selling stock?
Across all SEC Form 4 open-market filings on record, Michael H. Mulroy is a net buyer of $26,100, with 1 open-market purchase reported. The latest transaction was reported on Nov 17, 2026.
Which companies does Michael H. Mulroy report insider trades for?
Michael H. Mulroy has reported open-market trades in Lineage Cell Therapeutics, Inc. (LCTX). The latest SEC-reported relationship is Director of Lineage Cell Therapeutics, Inc. (LCTX).
Where does Michael H. Mulroy's insider trading data come from?
Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under reporting owner CIK 1509725, and refreshes this page daily.